Monopar Therapeutics (MNPR) Free Cash Flow (2017 - 2025)

Monopar Therapeutics has reported Free Cash Flow for 9 years, with the latest figure at -$3.4 million in Q4 2025.

• Quarterly Free Cash Flow fell 68.64% year-over-year to -$3.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$12.2 million (down 90.52% YoY) and the FY2025 annual result came in at -$12.2 million, down 90.52% from the prior year.
• Free Cash Flow retreated to -$3.4 million in Q4 2025 per MNPR's latest filing, from -$2.1 million in the prior quarter.
• Over five years, Free Cash Flow peaked at -$1.1 million in Q3 2024 and troughed at -$5.7 million in Q1 2025.
• A 5-year average of -$2.1 million and a median of -$1.9 million in 2021 frame the typical range for Free Cash Flow.
• The sharpest annual moves came in 2024 and 2025: Free Cash Flow soared 44.66% in 2024, then plunged 242.11% in 2025.
• Over 5 years, Free Cash Flow stood at -$2.0 million in 2021, then jumped by 35.93% to -$1.3 million in 2022, then decreased by 18.75% to -$1.5 million in 2023, then fell by 29.27% to -$2.0 million in 2024, then tumbled by 68.64% to -$3.4 million in 2025.
• According to Business Quant data, Free Cash Flow over the past three periods registered -$3.4 million, -$2.1 million, and -$1.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.